Business
Halberd Corporation Files International Patent Cooperation Treaty (PCT) Application Covering Extracorporeal Treatment of COVID-19 and Other Medical Maladies
Halberd Corporation Files International Patent Cooperation Treaty (PCT) Application Covering Extracorporeal Treatment of COVID-19 and Other Medical Maladies.
About this update from Halberd Corp.
[{"type":"text","content":"JACKSON CENTER, PA / ACCESSWIRE / March 18, 2021 / Halberd Corporation (OTC PINK:HALB) filed an International Patent Cooperation Treaty (PCT) application for coverage of the invention titled, "Method for Treating and Curing Covid-19 Infection." The Patent Cooperation Treaty has over 150 participating countries and allows an inventor to seek patent protection in numerous countries simultaneously.William A. Hartman, Chairman, President & CEO of Halberd Corporation, stated, "We believe this technology has sufficient merit to seek patent protection beyond the U.S. Through the PCT, we are able to protect our technology in many countries across the globe. Halberd's patented extracorporeal treatment process opens the door to treatment of Covid and other diseases through radiofrequency elimination (experimentation already underway with GreenBioAZ) or through laser ablation methodology being explored currently with a potential European technology source."The Halberd U.S. provisional patent application "Method for Treating and Curing Covid-19 Infection" was initially filed with the U.S. Patent and Trademark Office on March 16, 2020. Click here to read a simplified explanation of the treatment process associated with this provisional patent. Halberd holds exclusive worldwide license to this technology.To get the latest news on Halberd's exciting developments, subscribe by submitting this form.(https://halberdcorporation.com/contact-us/)For more information please contact:William A. [email protected];[email protected]:@HalberdCAbout Halberd Corporation.Halberd Corporation (OTC PINK:HALB), is a publicly-traded company on the OTC Market and is in full compliance with OTC Market reporting requirements. It is debt-free and holds the exclusive rights to several patent-pending COVID-19 extracorporeal treatments:Title Patent/ Application No. Filing DateStatus/Document*Method for Treating and Curing Covid-19 InfectionUS 62/98998103/16/2020Provisionalprovisional_COVID-19_kk,4823-1130-2071.docxPCT/US21/2254103/16/2021International PCT995-004PCT-Application-FINAL.pdf*Method for Treating Covid-19 Inflammatory Cytokine Storm for the Reduction of Morbidity and Mortality in Covid-19 PatientsUS 63/00720704/08/2020ProvisionalCytokine-provisional-kk,...